Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Time Trends in Simple Congenital Heart Disease Over 39 Years: A Danish Nationwide Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Outcomes in Antiplatelet-Associated Intracerebral Hemorrhage in the TICH-2 Randomized Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Long-Term Results After Drug-Eluting Versus Bare-Metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Phrenic Nerve Block on Severe Post-Hepatectomy Shoulder Pain: A Randomized, Double-blind, Placebo-controlled, Pilot Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Using machine learning for predicting intensive care unit resource use during the COVID-19 pandemic in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin

    Research output: Contribution to journalReviewResearchpeer-review

  4. Challenges in conducting paediatric trials with off-patent drugs

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background Intravenous high-dose glucagon is a recommended antidote against beta-blocker poisonings, but clinical effects are unclear. We therefore investigated hemodynamic effects and safety of high-dose glucagon with and without concomitant beta-blockade. Methods and Results In a randomized crossover study, 10 healthy men received combinations of esmolol (1.25 mg/kg bolus+0.75 mg/kg/min infusion), glucagon (50 µg/kg), and identical volumes of saline placebo on 5 separate days in random order (saline+saline; esmolol+saline; esmolol+glucagon bolus; saline+glucagon infusion; saline+glucagon bolus). On individual days, esmolol/saline was infused from -15 to 30 minutes. Glucagon/saline was administered from 0 minutes as a 2-minute intravenous bolus or as a 30-minute infusion (same total glucagon dose). End points were hemodynamic and adverse effects of glucagon compared with saline. Compared with saline, glucagon bolus increased mean heart rate by 13.0 beats per minute (95% CI, 8.0-18.0; P<0.001), systolic blood pressure by 15.6 mm Hg (95% CI, 8.0-23.2; P=0.002), diastolic blood pressure by 9.4 mm Hg (95% CI, 6.3-12.6; P<0.001), and cardiac output by 18.0 % (95% CI, 9.7-26.9; P=0.003) at the 5-minute time point on days without beta-blockade. Similar effects of glucagon bolus occurred on days with beta-blockade and between 15 and 30 minutes during infusion. Hemodynamic effects of glucagon thus reflected pharmacologic glucagon plasma concentrations. Glucagon-induced nausea occurred in 80% of participants despite ondansetron pretreatment. Conclusions High-dose glucagon boluses had significant hemodynamic effects regardless of beta-blockade. A glucagon infusion had comparable and apparently longer-lasting effects compared with bolus, indicating that infusion may be preferable to bolus injections. Registration Information URL: https://www.clinicaltrials.gov; Unique identifier: NCT03533179.

Original languageEnglish
JournalJournal of the American Heart Association
Volume9
Issue number21
Pages (from-to)e016828
ISSN2047-9980
DOIs
Publication statusPublished - 3 Nov 2020

ID: 61262225